Protagonist Therapeutics filings document formal disclosures for a biopharmaceutical company built around peptide therapeutics. Form 8-K reports furnish quarterly and annual financial results, corporate updates, Regulation FD presentations and material event exhibits tied to pipeline, collaboration and operating developments.
Proxy and annual meeting filings describe board elections, executive compensation votes, auditor ratification, equity incentive plan matters, stockholder voting results and the company's common stock voting structure. These records also frame governance, compensation and capital-related disclosures for Protagonist's Nasdaq-listed Delaware corporation.
PTGX has a planned sale of 108,273 common shares under Rule 144, with an aggregate market value of $9,162,061. The shares are to be sold through J.P. Morgan Securities LLC on the Nasdaq, with an approximate sale date of 01/23/2026, and the filing notes 62,515,666 shares of this class outstanding.
The person for whose account the securities will be sold acquired these shares directly from the issuer on 01/23/2026 via cash option exercises in two transactions of 30,000 and 78,273 shares. The signer represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Protagonist Therapeutics Chief Medical Officer Arturo Molina reported a sale of company stock. On January 20, 2026, he sold 9,514 shares of Common Stock at a price of $82.48 per share. The filing explains that this sale was made to cover the tax withholding obligation incurred when restricted stock units settled, meaning the transaction was tied to taxes rather than an open-market portfolio decision. After this sale, Molina beneficially owned 97,266 shares of Protagonist Therapeutics common stock in direct form.
Protagonist Therapeutics, Inc. President and CEO Dinesh V. Patel reported a sale of company common stock in a Form 4 filing. On January 20, 2026, he sold 34,438 shares of Protagonist Therapeutics common stock at a price of $82.48 per share, reported as a direct ownership transaction.
According to the footnote, the sale was made to cover tax withholding obligations incurred when restricted stock units settled, meaning it was tied to an equity award rather than an open-market discretionary sale of his broader holdings. After this transaction, Patel directly beneficially owned 580,505 shares of Protagonist Therapeutics common stock.
Protagonist Therapeutics Chief Financial Officer Asif Ali reported a sale of common stock in a Form 4 filing. On January 20, 2026, he sold 8,588 shares of Protagonist Therapeutics common stock at a price of $82.48 per share. According to the footnote, the sale was made to cover tax withholding obligations incurred when restricted stock units settled, meaning it was connected to equity compensation rather than a discretionary open-market sale. After this transaction, Ali beneficially owns 78,077 shares of the company’s common stock directly.
Protagonist Therapeutics (PTGX) stockholder Arturo Molina MD has filed a Rule 144 notice to sell 9,514 common shares through Morgan Stanley Smith Barney on NASDAQ. The planned sale has an aggregate market value of $784,714.72, compared with a total of 62,515,666 common shares outstanding. The shares relate to restricted stock that vested under a registered plan on 01/20/2026, with services rendered as the form of payment.
The form also discloses that the same seller previously sold 2,712 common shares on 11/17/2025 for gross proceeds of $229,896.24. By signing, the seller represents they are not aware of any undisclosed material adverse information about Protagonist Therapeutics’ operations.
A holder of PTGX common stock has filed a notice of proposed sale under Rule 144. The filing covers 34,438 shares of common stock, to be sold through Morgan Stanley Smith Barney on the Nasdaq, with an indicated aggregate market value of $2,840,446.24. The filing notes that there were 62,515,666 shares of this class outstanding at the time of the notice.
The shares to be sold were acquired on 01/20/2026 through the vesting of restricted stock under a registered plan, with “services rendered” listed as the form of payment. The person for whose account the securities are to be sold represents that they do not know of any material adverse, non‑public information about the issuer’s current or prospective operations.
A holder of the issuer’s common stock has filed a notice of proposed sale under Rule 144 for 8,588 shares. The planned sale is to be executed through Morgan Stanley Smith Barney on or about 01/20/2026, with an indicated aggregate market value of 708,338.24. The issuer reports 62,515,666 shares outstanding, which is a baseline figure for the company’s equity.
The shares to be sold were acquired as restricted stock vesting under a registered plan from the issuer on 01/20/2026, as compensation for services rendered. By signing the notice, the seller represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
Protagonist Therapeutics director Harold E. Selick reported exercising a stock option on 01/09/2026, converting 14,299 stock options with an exercise price of $4.21 into 14,299 shares of common stock. The transaction is coded “M,” indicating an option exercise.
Following this transaction, Selick directly beneficially owns 60,845 shares of Protagonist Therapeutics common stock. The filing notes that the stock options exercised were fully vested and that no derivative securities of this option grant remain outstanding.
Protagonist Therapeutics, Inc. reported that it has made an updated corporate presentation available as of January 12, 2026. The presentation is provided as Exhibit 99.1 to a current report on Form 8-K under Regulation FD, which is intended to share information broadly with the market. The company notes that this information, including the exhibit, is being furnished rather than filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other SEC filings.
Protagonist Therapeutics director William D. Waddill reported new equity awards from the company. On January 2, 2026, he received 2,695 restricted stock units of common stock at a price of $0, bringing his directly held common stock to 7,825 shares after the grant. These restricted stock units vest in full on January 15, 2027, as long as he continues serving the company.
He also received a stock option for 3,762 shares of common stock with an exercise price of $87.18 per share. The option vests in 12 equal monthly installments following January 2, 2026, subject to his continued service, and expires on January 2, 2036. Both awards are reported as directly owned.